Response to “Letter to the Editor Regarding: Patient Preferences for Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment”

Response to “Letter to the Editor Regarding: Patient Preferences for Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment”

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes therapy 2020-10, Vol.11 (10), p.2443-2446
Hauptverfasser: Brooks, Anne B., Langer, Jakob, Tervonen, Tommi, Peter Hemmingsen, Mads, Eguchi, Kosei, Bacci, Elizabeth D.
Format: Artikel
Sprache:eng
Schlagworte:
Cardiology
Diabetes
Endocrinology
Internal Medicine
Letter
Medicine
Medicine & Public Health
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2446
container_issue 10
container_start_page 2443
container_title Diabetes therapy
container_volume 11
creator Brooks, Anne B.
Langer, Jakob
Tervonen, Tommi
Peter Hemmingsen, Mads
Eguchi, Kosei
Bacci, Elizabeth D.
description
doi_str_mv 10.1007/s13300-020-00900-3
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7509018</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A651344921</galeid><sourcerecordid>A651344921</sourcerecordid><originalsourceid>FETCH-LOGICAL-c492t-db2eefab4f88a93db1feec9d8a0ab8f790defde71e16bfd5be3351efb2290f573</originalsourceid><addsrcrecordid>eNp9ks1u1DAUhSMEolXpC7BAltiURYp_Jn9dII2GMoAGMaqGteUk1zMuGTu1HUR3fRCQeBZWPEefhDtMmVKESBTF8f3usU98kuQxo8eM0uJ5YEJQmlKOD61wJO4l-6zMqzSvcnZ_N87EXnIYwjnFS1RVxdjDZE_wIi94Ue4nP84g9M4GINGR66svM4gR_OYjroCctiY6T85gqXxr7PKEzFU0YCOZe9DgwTYQiEZk2g2NWjqbduYjkDn00bSQMnI0nc1T9gwlGpxDcIyQCZEsPKi43kg5TRaXPXz_xslLo2qIKPkOus7EIRBjyVvVK3tCxlgNjccymaycaXB3n3vwZqNxffX1UfJAqy7A4c37IPnw6nQxeZ3O3k_fTMaztBlVPKZtzQG0qke6LFUl2pppgKZqS0VVXeqioi3oFgoGLK91m9UgRMZA15xXVGeFOEhebHX7oV5D2-DqXnWyx40ofymdMvJuxZqVXLpPssjwmFiJAkc3At5dDBCiXKMv9KssuCFIPhKsZIXIMkSf_oWeu8FbtCd5xrgocyZGt9RSdSCN1Q7XbTaicpxnSKBxhtTxPyi8W1ibxlnQBufvNPBtQ-NdCHjcO4-Myk0E5TaCEiMof0VQCmx68uff2bX8DhwCYgsELNkl-FtL_5H9CQh-60Y</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2512386134</pqid></control><display><type>article</type><title>Response to “Letter to the Editor Regarding: Patient Preferences for Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment”</title><source>DOAJ Directory of Open Access Journals</source><source>Springer Nature OA Free Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Brooks, Anne B. ; Langer, Jakob ; Tervonen, Tommi ; Peter Hemmingsen, Mads ; Eguchi, Kosei ; Bacci, Elizabeth D.</creator><creatorcontrib>Brooks, Anne B. ; Langer, Jakob ; Tervonen, Tommi ; Peter Hemmingsen, Mads ; Eguchi, Kosei ; Bacci, Elizabeth D.</creatorcontrib><identifier>ISSN: 1869-6953</identifier><identifier>EISSN: 1869-6961</identifier><identifier>DOI: 10.1007/s13300-020-00900-3</identifier><identifier>PMID: 32767278</identifier><language>eng</language><publisher>Cheshire: Springer Healthcare</publisher><subject>Cardiology ; Diabetes ; Endocrinology ; Internal Medicine ; Letter ; Medicine ; Medicine &amp; Public Health</subject><ispartof>Diabetes therapy, 2020-10, Vol.11 (10), p.2443-2446</ispartof><rights>The Author(s) 2020</rights><rights>COPYRIGHT 2020 Springer</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c492t-db2eefab4f88a93db1feec9d8a0ab8f790defde71e16bfd5be3351efb2290f573</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509018/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509018/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27903,27904,41099,42168,51555,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32767278$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brooks, Anne B.</creatorcontrib><creatorcontrib>Langer, Jakob</creatorcontrib><creatorcontrib>Tervonen, Tommi</creatorcontrib><creatorcontrib>Peter Hemmingsen, Mads</creatorcontrib><creatorcontrib>Eguchi, Kosei</creatorcontrib><creatorcontrib>Bacci, Elizabeth D.</creatorcontrib><title>Response to “Letter to the Editor Regarding: Patient Preferences for Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment”</title><title>Diabetes therapy</title><addtitle>Diabetes Ther</addtitle><addtitle>Diabetes Ther</addtitle><subject>Cardiology</subject><subject>Diabetes</subject><subject>Endocrinology</subject><subject>Internal Medicine</subject><subject>Letter</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><issn>1869-6953</issn><issn>1869-6961</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp9ks1u1DAUhSMEolXpC7BAltiURYp_Jn9dII2GMoAGMaqGteUk1zMuGTu1HUR3fRCQeBZWPEefhDtMmVKESBTF8f3usU98kuQxo8eM0uJ5YEJQmlKOD61wJO4l-6zMqzSvcnZ_N87EXnIYwjnFS1RVxdjDZE_wIi94Ue4nP84g9M4GINGR66svM4gR_OYjroCctiY6T85gqXxr7PKEzFU0YCOZe9DgwTYQiEZk2g2NWjqbduYjkDn00bSQMnI0nc1T9gwlGpxDcIyQCZEsPKi43kg5TRaXPXz_xslLo2qIKPkOus7EIRBjyVvVK3tCxlgNjccymaycaXB3n3vwZqNxffX1UfJAqy7A4c37IPnw6nQxeZ3O3k_fTMaztBlVPKZtzQG0qke6LFUl2pppgKZqS0VVXeqioi3oFgoGLK91m9UgRMZA15xXVGeFOEhebHX7oV5D2-DqXnWyx40ofymdMvJuxZqVXLpPssjwmFiJAkc3At5dDBCiXKMv9KssuCFIPhKsZIXIMkSf_oWeu8FbtCd5xrgocyZGt9RSdSCN1Q7XbTaicpxnSKBxhtTxPyi8W1ibxlnQBufvNPBtQ-NdCHjcO4-Myk0E5TaCEiMof0VQCmx68uff2bX8DhwCYgsELNkl-FtL_5H9CQh-60Y</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Brooks, Anne B.</creator><creator>Langer, Jakob</creator><creator>Tervonen, Tommi</creator><creator>Peter Hemmingsen, Mads</creator><creator>Eguchi, Kosei</creator><creator>Bacci, Elizabeth D.</creator><general>Springer Healthcare</general><general>Springer</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20201001</creationdate><title>Response to “Letter to the Editor Regarding: Patient Preferences for Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment”</title><author>Brooks, Anne B. ; Langer, Jakob ; Tervonen, Tommi ; Peter Hemmingsen, Mads ; Eguchi, Kosei ; Bacci, Elizabeth D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c492t-db2eefab4f88a93db1feec9d8a0ab8f790defde71e16bfd5be3351efb2290f573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Cardiology</topic><topic>Diabetes</topic><topic>Endocrinology</topic><topic>Internal Medicine</topic><topic>Letter</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><toplevel>online_resources</toplevel><creatorcontrib>Brooks, Anne B.</creatorcontrib><creatorcontrib>Langer, Jakob</creatorcontrib><creatorcontrib>Tervonen, Tommi</creatorcontrib><creatorcontrib>Peter Hemmingsen, Mads</creatorcontrib><creatorcontrib>Eguchi, Kosei</creatorcontrib><creatorcontrib>Bacci, Elizabeth D.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetes therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brooks, Anne B.</au><au>Langer, Jakob</au><au>Tervonen, Tommi</au><au>Peter Hemmingsen, Mads</au><au>Eguchi, Kosei</au><au>Bacci, Elizabeth D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Response to “Letter to the Editor Regarding: Patient Preferences for Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment”</atitle><jtitle>Diabetes therapy</jtitle><stitle>Diabetes Ther</stitle><addtitle>Diabetes Ther</addtitle><date>2020-10-01</date><risdate>2020</risdate><volume>11</volume><issue>10</issue><spage>2443</spage><epage>2446</epage><pages>2443-2446</pages><issn>1869-6953</issn><eissn>1869-6961</eissn><cop>Cheshire</cop><pub>Springer Healthcare</pub><pmid>32767278</pmid><doi>10.1007/s13300-020-00900-3</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1869-6953
ispartof Diabetes therapy, 2020-10, Vol.11 (10), p.2443-2446
issn 1869-6953
1869-6961
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7509018
source DOAJ Directory of Open Access Journals; Springer Nature OA Free Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Cardiology
Diabetes
Endocrinology
Internal Medicine
Letter
Medicine
Medicine & Public Health
title Response to “Letter to the Editor Regarding: Patient Preferences for Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment”
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T14%3A07%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Response%20to%20%E2%80%9CLetter%20to%20the%20Editor%20Regarding:%20Patient%20Preferences%20for%20Glucagon-like%20Peptide-1%20(GLP-1)%20Receptor%20Agonist%20Treatment%20of%20Type%C2%A02%20Diabetes%20Mellitus%20in%20Japan:%20A%20Discrete%20Choice%20Experiment%E2%80%9D&rft.jtitle=Diabetes%20therapy&rft.au=Brooks,%20Anne%20B.&rft.date=2020-10-01&rft.volume=11&rft.issue=10&rft.spage=2443&rft.epage=2446&rft.pages=2443-2446&rft.issn=1869-6953&rft.eissn=1869-6961&rft_id=info:doi/10.1007/s13300-020-00900-3&rft_dat=%3Cgale_pubme%3EA651344921%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2512386134&rft_id=info:pmid/32767278&rft_galeid=A651344921&rfr_iscdi=true